<table>
<thead>
<tr>
<th>Title</th>
<th>Aggressive ovarian plasmacytoma resistant to radiation and chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Yamasaki, Kentaro; Miura, Kiyonori; Abe, Kuniko; Masuzaki, Hideaki</td>
</tr>
<tr>
<td>Citation</td>
<td>Acta medica Nagasakiensia, 58(1), pp.9-12; 2013</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2013-04</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/32064">http://hdl.handle.net/10069/32064</a></td>
</tr>
</tbody>
</table>
Aggressive ovarian plasmacytoma resistant to radiation and chemotherapy

Kentaro YAMASAKI¹, Kiyonori MIURA¹, Kuniko ABE², Hideaki MASUZAKI¹

¹Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
²Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

We present a case of ovarian plasmacytoma resulting in the patient's death by very quick progression after the operation, radiation and chemotherapy. As reported cases of primary ovarian plasmacytoma are very rare, its prognosis remains unknown. To date, we found seven reports of solitary ovarian plasmacytoma. Except for our case, most cases showed relatively slow progression or need only strict observation without recurrence. Although post-surgical therapy of ovarian plasmacytoma is not clearly established, our case was needed to use radiation and chemotherapy against the very rapid recurrent tumor. In this case, ovarian plasmacytoma relapsed very quickly, suggesting that some cases of ovarian plasmacytoma may require an aggressive adjuvant therapy.

Address correspondence: Kiyonori Miura, MD, PhD, Department of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan
Phone: +81-95-819-7365, Fax: +81-95-819-7365, E-mail kiyonori@nagasaki-u.ac.jp

Received November 7, 2012; Accepted December 17, 2012

Keywords: adjuvant radiotherapy, lymphoproliferative disorders, neoplasms, ovarian tumor, plasmacytoma
large mass originated from the right ovary and had firm adhesions with the sigmoid colon and rectum. The tumor could not be totally resected because of cancerous adhesions, and there was a residual tumor measuring 3 cm on the serosa of the sigmoid colon. The resected specimen consisted of a solid tumor measuring 10 cm. The tumor was partly smooth-surfaced and partly covered by adhesions. The cut surface was yellow and lobulated. Cysts were present in half of the tumor with pus-like yellowish fluid. Histopathology showed sheets of atypical round cells with faint acidophilic to basophilic cytoplasm (Figure 2). Immunohistochemistry showed the cells to be positive for plasmacyte marker, IgCD10, CD56, γ- immunoglobulin light chains and IgG, but negative for PLAP, AE1/AE3, AFP, CD3, CD57, CD15 and other tumor markers. No malignancy was detected in the biopsy sample of the omentum.

Although there was the possibility of a metastatic ovarian plasmacytoma arising from bone marrow, a bone scintigam was negative and the bone marrow biopsy showed no abnormal cells. Monoclonal paraprotein was not detected and the tumor was diagnosed as a primary plasmacytoma of the ovary. At the 2nd week after operation, the patient continued to complain of abdominal distension and an MRI scan showed that the tumor was still growing with multiple metastatic nodules in her pelvis despite the original resection (Figure 3). Therefore, radiation therapy was administered after constructing a colostomy, which was not affected by radiation. Radiotherapy for whole pelvis and para-aorta was planned to be administered at a dose of 30.0 Gy in 20 fractions in the each field. However, the tumor continued to grow during the therapy. The radiation therapy was suspended at the 15th fraction of the total 20 planed fractions. Then, chemotherapy with Paclitaxel (80mg/m2/every week) and Carboplatin (AUC5/every 3weeks) was administered from the 4th week after surgery. The tumor continued to proliferate and the patient died of multiorgan failure at 2.5 months after the first operation.

![Figure 1](image1.png)
**Figure 1.** A 65-year-old woman with a large pelvic mass diagnosed as an ovarian plasmacytoma. Preoperative sagittal T1-weighted (A) and sagittal T2-weighted (B) magnetic resonance imaging (MRI) scan of the pelvis. There was ascites and an irregularly shaped ovary: half polycystic and half comprising a solid mass measuring 10 × 7 × 9 cm.

![Figure 2](image2.png)
**Figure 2.** Histopathology showed a diffuse proliferation of atypical large lymphoid cells with round or oval nuclei, small nucleoli and abundant cytoplasm. Mitotic figures were frequent (hematoxylin and eosin staining; ×400 magnification).
Discussion

EMPs are rare neoplasms and 80-90% have been reported as developing in the head or neck. Their diagnostic criteria are: diagnosis of a plasma cell tumor proven by pathology, absence of bone or other tissue involvement, bone marrow biopsies showing plasma cell infiltration not exceeding 5% of all nucleated cells and a low concentration of M-protein. Our case satisfied all of these criteria together with immunohistochemistry results and was diagnosed as a primary ovarian plasmacytoma. Emery et al. reviewed the seven reported cases using the guidelines of International Federation of Gynecology and Obstetrics (FIGO), but excluded one from 1938. All reported tumors were large and most were over 12 cm in size except for one that was reported as "fist-sized" in 1938. The tumor in our case was also large, but it was detected before it grew over 12 cm in diameter. Four previous cases involved only the left ovary; one patient had bilateral ovarian tumors and the laterality of the other two cases is unknown. Here the tumor arose from the right ovary. Emery et al. reported that five patients had FIGO stage I disease and one patient with stage III disease died 3 months after surgery. Four patients with stage I tumors were followed for 9-24 months while one patient with a stage I tumor was lost to follow-up. Although there are no clear guidelines for treating EMPs, radiotherapy is effective for localized tumors. The median overall survival or recurrence-free survival for patients with radiation-treated EMPs was 150 months. EMPs in areas outside the upper aerodigestive tract were resected by surgery in 55.6% of cases, treated by radiation in 11.1% and treated combined by surgery and radiation in 19.8%. In 64.7% of these cases there was no recurrence. Our patient had a FIGO stage IIc tumor that showed very rapid recurrence plus resistance to radiation therapy; this has not been reported before. The tumor in our case and the stage III tumor reported by Bambirra et al. could not be resected successfully and both patients died around 3 months after surgery. It is difficult to recommend a therapeutic strategy for primary ovarian plasmacytomas based on these very few cases. Regarding the initial management of ovarian cancer, complete resection or maximum debulking surgery is recommended as much as possible. Subsequently, adjuvant therapy is performed in most cases except stage Ia ovarian cancer patients. Therefore, a biopsy gives us much important information for adjuvant therapy, because which kind of chemotherapies and/or radiation therapies should be selected as adjuvant therapy depends on the type of pathological findings. However, our case of ovarian plasmacytoma relapsed very quickly despite a maximum debulking surgery followed radiochemotherapy, suggesting that some cases of ovarian plasmacytoma may require an aggressive adjuvant therapy. Also, there is a possibility that aggressive surgery causes a disseminated relapse of ovarian plasmacytoma. Therefore, it may be very useful to estimate which is aggressive ovarian plasmacytoma without a biopsy. Further work isolating another diagnostic tools such as a tumor-specific molecular marker, e.g. DNA, mRNA or microRNA, in plasma will be key to a better understanding of how ovarian plasmacytoma should be manage.

Acknowledgements

This study was supported by the Nagasaki University President's Fund Grant. K.Y., K.M., S.M. and H.M. were supported by JSPS KAKENHI, grant numbers No.24791711, 23592406, 24791712 and 22591827, respectively. The authors have no conflicts of interest to disclos.

References


